An interventional study of Nasopharyngeal swab and Questionnaire in Nosocomial Infections, sponsored by Hospices Civils de Lyon. Recruiting at 6 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.
Among the 47 studies in Cross Infection with a site in France, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 14 with no phase, and was the 43rd registered.
287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.
Browse Cross Infection studies →8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 1,000 is above the median of 193 across 170 interventional studies indexed under Cross Infection.
Median enrollment 244 across the 23 interventional studies, 496 across the 24 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 4 studies filed under Cross Infection — fewer than ten, so there is no comparison to draw.
4 of the studies in Cross Infection with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06482463University Hospital, ToulouseDiagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis | 2027-02 |
| NCT06643039Hospices Civils de LyonNosocomial Respiratory Virus Infection | 2027-07-05 |
| NCT07822971Centre Hospitalier Régional Metz-ThionvilleImpact of an On-site Simulation-based Training Programme on Adherence to Standard Precautions and Healthcare-associated Infections in Adult Intensive Care | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Cross Infection with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.
To date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals/patients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.
We will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.
The main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.
Volunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).
For each patient/health care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered "cases" and patients tested negative as "controls".
The collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.
The prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.
The results of this research project will allow to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF.
Biological: Nasopharyngeal swab · Other: Questionnaire
Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF
Biological: Nasopharyngeal swab · Other: Questionnaire
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
Incidence of hospital-acquired respiratory viral infections
The primary endpoint will be evaluated by calculating the incidence of hospital-acquired respiratory viral infections overall and by type of virus (influenza, COVID-19, RSV) during the surveillance period. incidence rate will be estimated by the ration of number of incident cases over the study period to the cumulative observation time (in person-weeks) of hospitalized patients. Incidence density will be estimated by the ratio of number of incident cases during successive weekly observation periods to the cumulative observation times calculated over the same periods.
Time frame: At inclusion
Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Of 59 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 31 months is above that.
Counting every sponsor, half of 61 studies reached it within 16 months; a quarter within 7 and three quarters within 29.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.